(Q35595091)

9 August 2017

1 reference

title

Review of the unique properties of budesonide (English)

1 reference

9 August 2017

Edward J O'Connell

1

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

published in

Clinical Therapeutics

1 reference

9 August 2017

volume

25 Suppl C

1 reference

9 August 2017

page(s)

C42-60

1 reference

Asthma therapy in the new millennium

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Anti-inflammatory actions of steroids: molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Pharmacological factors that influence the choice of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Structure-activity relationships of topically active steroids: the selection of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

The human pharmacology of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

A comparison of the efficacy and safety of inhaled corticosteroids in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line In vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Prolonged airway activity and improved selectivity of budesonide possibly due to esterification.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Japanese Pulmicort Turbuhaler study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Daily regimen and compliance with treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Results of pulmonary valvotomy and infundibular resection in 100 cases of Fallot's tetralogy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Efficacy of once-daily versus twice-daily administration of budesonide by Turbuhaler(R) in children with stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Asthma quality of life during 1 year of treatment with budesonide with or without formoterol.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Budesonide Turbuhaler delivered once daily improves health-related quality of life and maintains improvements with a stepped-down dose in adults with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) is effective and safe in adults previously treated with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Nebulised budesonide in severe infantile asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

The inhalation device influences lung deposition and bronchodilating effect of terbutaline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Peak inspiratory flow through Turbuhaler in acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler in children with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Lung deposition of budesonide from turbuhaler in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Local side-effects during 4-year treatment with inhaled corticosteroids--a comparison between pressurized metered-dose inhalers and Turbuhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Fluticasone propionate 750 micrograms/day versus beclomethasone dipropionate 1500 micrograms/day: comparison of efficacy and adrenal function in paediatric asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Limitations of short-term studies in predicting long-term adverse effects of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Long-term effects of budesonide or nedocromil in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Effect of inhaled steroids on bone mineral density: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Use of inhaled corticosteroids and the risk of cataracts.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Association of inhaled corticosteroid use with cataract extraction in elderly patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

The risk of cataract among users of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Congenital malformations after the use of inhaled budesonide in early pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

Therapeutic margin of budesonide in patients with mild to severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980305-3

7 January 2021

10.1016/S0149-2918(03)80305-3

Identifiers

DOI

1 reference

9 August 2017

1 reference